A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Immune Globulin (Human) 10% (Gamunex-C) PEG Process (IVIG-PEG) Compared to Gamunex-C in Participants With Primary Humoral Immunodeficiency
Clinical trial NCT04561115 · COMPLETED
Trial details
- NCT number
- NCT04561115
- Sponsor
- Grifols Therapeutics LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-02
- Primary completion
- 2022-03-28
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.